Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway
- 180 Downloads
Chronic myelogenous leukemia is a neoplasm of myeloid progenitor cells. We recently found that rapamycin could induce G0/G1 phase arrest and apoptosis and inhibit proliferation of K562 cells through inhibiting mammalian target of rapamycin (mTOR) pathway. However, whether rapamycin has synergistic effects with other drugs in chronic myelogenous leukemia (CML) therapies remain unclear. Therefore, we examined the effect of rapamycin combined with celecoxib on K562 cells in vitro. The survival rates showed a significant decrease in rapamycin + celecoxib treatment group. The combination treatment also increased the G0/G1 phase cells as compared to rapamycin or celecoxib treatment alone (P < 0.05), accompanied with the decreased population of S phase cells. Meanwhile, the rate of apoptosis was 15.87 ± 2.21 % in rapamycin + celecoxib treatment group, significantly higher than that in mono treatment group (P < 0.05). Western blot and reverse transcription PCR (RT-PCR) analysis showed that the expressions of mTOR, 4E-BP1, and p70S6K were all significantly decreased in K562 cells after rapamycin + celecoxib treatment (P < 0.05). In conclusion, rapamycin combined with celecoxib could induce cell cycle arrest and apoptosis and decrease the expressions of mTOR, 4E-BP1, and p70S6K. It suggested that the combination could enhance the antitumor effects of mono treatment on CML cells through downregulating mTOR pathway.
KeywordsChronic myelogenous leukemia mTOR Rapamycin Celecoxib
Conflicts of interest
- 14.Li J, Hao H, Xue L, Wang C, Wang S, Wang R. Expression and significance of COX-2, bcl-2, caspase-3 in diffuse large B-cell lymphoma. J Leuk Lymphoma. 2009;18(4):223–5.Google Scholar
- 15.Li J, Xue L, Wang C, Wang R, Yang J, Hao H. Effects of celecoxib on proliferation, apoptosis and VEGF expression in NB4 cells. Cancer Res Prev Treat. 2013;40(2):147–50.Google Scholar
- 24.Fan X, Takahashi-Yanaga F, Morimoto S, Zhan DY, Igawa K, Tomooka K, et al. Celecoxib and 2,5-dimethyl-celecoxib prevent cardiac remodeling inhibiting Akt-mediated signal transduction in an inherited dilated cardiomyopathy mouse model. J Pharmacol Exp Ther. 2011;338(1):2–11.CrossRefPubMedGoogle Scholar